Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)

Wyeth

Status and phase: Completed; Phase 1

Conditions: Depressive Disorder, Major

Treatments: Drug: Desvenlafaxine Sustained Release (DVS SR)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00440427

3151A2-1201

Details and patient eligibility

About

To assess the initial pharmacokinetic profile of single doses of 25mg and 50 mg of DVS SR to healthy subjects.

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

• Men or non-pregnant, non-lactating women
• Body mass index 18 - 30 kg/m2
• Body weight greater than or equal to 60kg

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)